Benjamin McLeod, Founder at Convey Bio, Fractional Chief Commerical Officer at Flyte Bio, shared a post on LinkedIn:
”Breaking News:
The FDA approved the world’s FIRST precision-engineered ALLOGENEIC cell therapy.
The therapy:
- Orca Bio’s TREGZI
- For adults with blood cancers heading into a stem cell transplant.
This is a big deal.
Allogeneic transplant can cure blood cancers…
But chronic GVHD haunts survivors for years.
The donor immune system turns on the patient’s own body.
Orca Bio cracked this by precision-engineering the graft itself, controlling exactly which cells go into the patient.
Technical Details:
- TREGZI is clinically known as Orca-T, a personalized product built from each donor’s cells
- In the pivotal Precision-T study, patients receiving TREGZI were twice as likely to be alive without chronic GVHD at one year versus conventional allogeneic transplant
- This is Orca Bio’s first approved therapy, validating its high-precision platform
Allogeneic is finally starting to mature.
What are your thoughts on this?
Drop them in the comments.
Other articles about Hematology on OncoDaily.